Axsome Therapeutics (AXSM) said Monday that its migraine drug Symbravo achieved the primary endpoint in a phase three trial, showing statistically significant improvements in overall quality of life and daily functioning compared with oral calcitonin gene-related peptide, or CGRP inhibitors, as measured by the Migraine-Specific Quality of Life Questionnaire.

The trial showed that 47.9% of patients achieved pain freedom within two hours with Symbravo compared with 1% on oral CGRP inhibitors, the company said. Additionally, 47.9% sustained pain relief from migraine for at least 24 hours with Symbravo versus 16.7% with CGRP inhibitors.

The trial also demonstrated that 51% of patients after treatment with Symbravo were able to resume normal activities quickly, compared to 11.5% on oral CGRP inhibitors, Axsome said.

Axsome said Symbravo was "well tolerated", with the most common adverse events being fatigue, nausea, vomiting, muscle tightness, and dizziness.